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Abstract 
 
Despite major advances in deciphering the neuropathological hallmarks of 
amyotrophic lateral sclerosis (ALS), validated neurochemical biomarkers for 
monitoring disease activity, earlier diagnosis, defining prognosis and unlocking key 
pathophysiological pathways are lacking.  Although several candidate biomarkers 
exist, translation into clinical application is hindered by small sample numbers, 
especially longitudinal, for independent verification. This review considers the 
potential routes to the discovery of neurochemical markers in ALS, and provides a 
consensus statement on standard operating procedures that will facilitate multi-
centre collaboration, validation and ultimately clinical translation. 
Page 4 of 33
URL: http://mc.manuscriptcentral.com/als  Email: gerd.halvorsen@informa.com
Amyotrophic Lateral Sclerosis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Otto et al. 
4 
 
Introduction 
 
It has been nearly half a century since the first published putative biomarker for 
amyotrophic lateral sclerosis (ALS), namely the observation of altered serum levels 
in response to oral arginine compared with controls (1).  Many and varied candidates 
have subsequently emerged as a result of advances in molecular biological and 
other analytical techniques (2-4).  This has resulted from a greater understanding of 
the underlying molecular mechanisms, but also improved clinical recognition and 
characterization of the heterogeneous syndrome of ALS (5). Currently riluzole is the 
only disease-modifying drug licensed for treatment of ALS and the focus of 
management from diagnosis is palliative.  Future therapeutic agents may come with 
inherent toxicities that require monitoring and adjustment of dose or choice of drug.  
As well as radically changing the nature and focus of ALS clinics, such a therapeutic 
era will place even greater reliance on robust biomarkers upon which to base such 
decisions. The concept of a recognisable ‘ALS signature’ is attractive, with the 
corollary of earlier perhaps ultimately preventative intervention.  However, the 
inherent clinical heterogeneity, the lack of understanding of those at risk and where 
the ‘clinical horizon’ lies in relation to the earliest pathogenic events, present major 
challenges to translation of candidates into clinically meaningful biomarkers. 
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What is the aim? 
 
The ideal ALS biomarker characteristics are summarized in Table 1. Biomarkers with 
diagnostic utility may assist primary care physicians or general neurologists to more 
rapidly refer a patient to a specialized ALS clinic. Those sensitive to disease activity 
might shorten clinical trials, more rapidly halting non-effective drug trials and 
potentially enabling patients to enroll in multiple trials.  ALS biomarkers have 
potential value on several levels, but the clinical benchmarks are already high (see 
Table 2). Moreover the history of biomarker discovery in human disease to date is 
sobering, with <0.01% of the number of published papers containing multiple 
candidates estimated to have been translated into biomarkers in routine clinical use 
(6). 
 
National and international collaborations are required to obtain the numbers of 
samples necessary to perform large biomarker validation studies for rare disorders 
like ALS (2).  A recent initiative resulted in consensus guidelines for neuroimaging 
biomarkers in ALS (7), and ALS biobanking efforts have been initiated in some 
countries e.g. the Northeast ALS consortium (NEALS) BioBank 
(www.alsconsortium.org) (8). However, standardized protocols of sample collection 
and annotated clinical information are not currently uniform and limit the ability to 
share samples and information.  The Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) standardized procedures for the collection, processing, storage and shipment 
of biofluid samples, from which a consortium identified CSF biomarkers for the early 
disease currently being validated in large studies.  In addition, a consensus protocol 
to collect and bank CSF for chronic inflammatory diseases and for a wider diagnostic 
spectrum of disorders has been recently published (9).  
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Study design 
 
The design of ALS biomarker studies is critical, whether the primary outcome is the 
generation of candidate biomarkers, or establishing the place of pre-defined markers 
within the current clinical management or therapeutic intervention (Figure 1).  
 
Cross-sectional studies and homogeneity 
 
Comparison of patients with a selected control group at a single time point may 
identify biomarkers that are enriched or depleted in ALS.  This strategy can be useful 
for identifying potential diagnostic markers or pathogenic pathways. These designs 
will not have value for identifying markers of therapeutic response or prognosis 
without continued clinical monitoring. The yield from group comparison may be 
reduced as a consequence of the heterogeneity in ALS (and compounded by small 
sample size), however attempts to select patients with homogeneous phenotype are 
not without their own problems. Grouping of patients by site of symptom onset (e.g. 
bulbar versus limb) may have value as a broad prognostic marker. Realistically, 
however, there is no evidence for a distinct pathogenesis in terms of site of onset, 
nor between regional phenotypes e.g. ‘flail arm’, so separation of groups by onset 
phenotype may be artificial.  Equally, rigid adherence to revised El Escorial criteria  
categories does not equate to homogeneity in terms of prognosis. Furthermore such 
criteria exclude those without mixed upper and lower motor neuron signs clinically, 
despite general acceptance that Progressive Muscular Atrophy and Primary Lateral 
Sclerosis form a continuum with ALS at a pathological level. Age at symptom onset 
and other established prognostic surrogates such as referral delay are potential 
confounds within an otherwise homogeneous ALS group. Whilst the exploration of 
sub-groups stratified according to a variety of criteria may still be of interest, a ‘real 
world’ approach to biomarker development is advocated that seeks to be meaningful 
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in translation to clinical practice, reflecting the natural spectrum of clinical phenotype 
common to many diseases within diverse human populations.  This approach may 
require multivariate modeling in larger groups of patients to control for known 
prognostic factors, and emphasizes the need for rigorous (though not unduly 
onerous) clinical information gathering.  
 
Choice of controls 
 
The selection of controls must be based on the scientific question, and not simply on 
the ease of availability of samples. Possible sources are listed in Table 3. Control 
samples as a rule are likely to be more meaningful if matched for age and gender, 
especially for an age-related condition like ALS.  Some controls (e.g. spouses) will 
have the advantage of additional matching for environmental factors. Obtaining more 
than one control for every patient enrolled is recommended.  It must be carefully 
considered whether to use blood relatives of patients as controls, even when 
studying apparently sporadic cases, as biomarkers might in theory be present in both 
the patient and an unaffected relative with an occult genetic predisposition.  The 
establishment instead of specific repositories for samples from pre-symptomatic 
relatives of patients with known ALS-associated gene mutations is advocated, being 
a potentially powerful resource in understanding the earliest steps in pathogenesis 
and achieving the larger goal of disease prevention.  This will require significant and 
sustained funding as well as a robust ethical and counseling framework. 
  
Longitudinal studies 
 
Multiple sampling over time in individual patients is the gold standard for assessing 
the usefulness of any biomarker as a prognostic indicator or marker of disease 
progression.  It may not be an essential requirement to have a separate control 
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group in longitudinal studies, since each patient can serve as their own control, with 
the change in value over time of a biomarker being the most relevant measure.  The 
sampling interval must be a balance between the improved statistical robustness of 
multiple time points and the practicality of repeated sampling in patients who become 
increasingly disabled.  Easily obtainable samples (e.g. blood, urine, saliva) might 
reasonably be sought every three months, whereas six-monthly or annual sampling 
is more realistic for more invasive procedures (e.g. cerebrospinal fluid (CSF), skin or 
muscle biopsy). At present neurofilaments have been confirmed independently by a 
number of groups to be of prognostic and diagnostic value (e.g.  (10, 11))(12, 13). 
Therefore we recommend the quantification of the very stable neurofilament heavy 
chain to be included in longitudinal studies.  Apart from diagnostic use this will allow 
comparison of studies, benchmarking of other candidates and emerging biomarkers 
and if absent indicate poor sample quality. Flexibility in timing of repeated samples, 
and continued clinical record keeping in those who withdraw from the sampling 
aspects of the study are essential. 
 
Clinical data collection 
 
Biomarker studies are of limited or no use without reliable clinical characterization of 
patients and any controls, but exhaustive requirements for clinical data recording at 
sampling are generally a disincentive for busy physicians, and may discourage multi-
center participation.  Defining a ‘minimal’ dataset is critical prior to a longitudinal 
study (see table 4), where the anonymization procedures involved in multi-site 
studies generally preclude returning to individual subject clinical records at a later 
date. 
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Choice of samples 
 
Although blood and CSF are currently the leading candidate sources for biomarkers 
across a range of neurological disorders, there are other sources in which relevant 
biomarkers are present. ALS biomarker research can be performed on urine 
samples, skin fibroblasts, muscle biopsy and post-mortem tissue samples. Each of 
these starting materials offers particular advantages and disadvantages (see table 
5).   
 
Standard operating procedures 
 
Standard operating procedures (SOPs) must be utilized for the collection, processing 
and storage of biofluid and tissue samples to be used in biomarker discovery and 
validation efforts. These SOPs must be established in each laboratory. Acceptable 
SOPs for CSF have recently been published (9).  SOPs for blood collection and 
storage procedures are also established. Although questions remain regarding the 
value and practicality of standardizing fasting status and time of day for sample 
collection, such information, along with the processing ‘time-to-freezer’ should be 
recorded and linked to all samples in a database. All biofluids should be collected in 
polypropylene tubes with screw caps and stored at -80 degrees Celsius.  While not 
all groups may be able to follow exactly identical collection, processing and storage 
protocols, it is crucial to at least record the volume and precise nature of the tissue 
sample.  This provides opportunities to utilize search parameters within the biobank 
repository to optimize the samples retrieved and used in research studies. Any 
protocol exceptions should be recorded to permit research studies on the most 
homogeneous set of samples. 
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Cerebrospinal fluid (CSF) 
 
A majority of ALS biomarker discovery research has been performed using CSF (for 
reviews see  (2-4)). A frankly traumatic tap should be recorded, and good practice is 
to discard the first 2 ml to minimise occult blood contamination (this can be sent for 
routine laboratory CSF parameters such as cell counts, total protein, albumin and 
lactate, with paired serum). Latter measurement can be used for internal and 
external quality control of biosamples (14).  Larger volumes of CSF are most helpful 
and there is no risk in removing up to 20 ml. Less than 5 ml can adversely affect 
quantitative measures measures due to gradient effects.. The incidence of life-
threatening complications of lumbar puncture (in those without standard clinical 
contraindications) is negligible. Significant post-procedure headache is uncommon 
with the use of 22G or narrower needle guage, and largely self-limiting within 72 
hours when it occurs. In one research study there was an incidence of only 2.5% in a 
cohort of over 1000 AD study subjects (15), and so concern about complications 
should not be seen as an ethical barrier per se to the extraction of this valuable 
biomarker source. 
 
The importance of rapidly centrifuging the CSF has been shown demonstrated in 
studies that identified rapid generation of proteomic and metabolomic artifacts (16, 
17).  The supernatant should be quickly aliquoted into polypropylene screw cap 
tubes and frozen within an hour.  CSF should be centrifuged with a speed of up to 
2,000 g  for at least 10 minutes (at 4°C if the resources are available), to pellet any 
cells and avoid their lysis with subsequent thawing. Prompt CSF handling is also 
important to minimize observed variations in pH (18).    
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Blood 
 
The standardization of protocols for sampling, processing and storage must be 
tailored to the different blood components and bio-assays potentially relevant to the 
search for biomarkers in ALS.  The blood collection tube type will determine if whole 
blood, serum or plasma has been processed for banking. Since hormonal circadian 
rhythm and diet are likely to influence the bioavailability of different compounds and 
of the gene expression in blood, a morning fasting blood sample may be ideal 
although probably not always possible during the regular follow up of ALS patients.  
RNA analyses and metabolomics are thought to be most sensitive to time of day and 
the fasting state at collection. Proteomic analysis is less sensitive and DNA analysis 
least.  
 
The impact of pre-analytical handling on mRNA gene expression has been evaluated 
with regards to the effects of delays to freezing and the buffers.  Storage of whole 
blood at −80°C is recommended, in either PAX-gene tubes or in RNAlater highly 
saline solution, the latter used in RNase-free microfuge tubes in which the RNAlater 
solution is three folds the volume of blood.  Red cells as a by-product of whole blood 
centrifugation during plasma extraction can be safely pooled into plastic tubes and 
stored at −80°C.  This simple protocol allows lipid chemistry analysis in red cells.  
White cell separation may provide the best source for DNA/RNA extraction or serve 
as a test-bed in the search of peripheral inflammatory markers in ALS.  Protocols for 
white cells separation can be implemented provided that the lab is equipped with the 
appropriate cryopreservation facilities (19).   
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Urine 
 
Urine is an easily obtained source of potential biomarkers.  Since urinary tract 
infections or an asymptomatic bacteriuria can negatively affect the results, the semi-
quantitative determination of basic urine parameters including erythrocytes, 
leukocytes, protein, pH, and nitrite is mandatory. Although a 24-hour urine collection 
might be the ideal for quantitative analysis of urinary proteins, it is less practicable. 
Collection of morning urine (that includes biochemical substances from several 
hours’ urine production) is recommended to overcome potential issues relating to 
diurnal variation. The second morning urine is recommended, as this reduces 
contamination of proteins from bacteria or bladder epithelial cells.  The use of the 
creatinine ratio may compensate for 24-hour urine collection. A correction factor of 
1.2 was proposed due to a lower creatinine excretion in females.  
 
Muscle 
 
Muscle biopsies prepared for routine clinical histopathologic studies are flash-frozen 
in liquid nitrogen, prepared for electron microscopy, or fixed in formalin following 
procurement and stained according to rigorous SOPs.  However, the histopathologic 
changes described in ALS are non-specific, occur late in the disease, and can often 
be measured less invasively with electrodiagnostic testing.  Furthermore it remains 
unknown whether muscle damage in ALS is due to unique biochemical pathways 
within the muscle or non-specific changes reflecting denervation (20).  Thus, 
biomarker discovery on muscle tissue is likely to take the form of proteomic, 
metabolomic, gene expression, or other novel techniques. 
 
Post-mortem tissues 
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The provision of high quality post-mortem brain and spinal cord tissue from patients 
with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases is 
vital to future research into the causes and treatment of these devastating illnesses.  
Such material is of particular importance in the elucidation of the molecular 
mechanisms involved in disease pathogenesis, and can verify the source of 
biomarker candidates identified in biofluids.  Studies on post-mortem CNS tissue are 
complementary to experiments in animal and in vitro models, and may provide the 
only confirmation of disease relevance.  In vivo imaging techniques might also 
benefit from validation through post-mortem examination.  High quality work using 
post-mortem material can only be performed if the tissue is preserved soon after 
death and in such a way as to allow a wide range of techniques to be later applied to 
it, including mRNA extraction, protein studies, in situ hybridization, 
immunocytochemistry or laser capture microdissection; and fixed and/or paraffin 
embedded tissue blocks for histology and immunohistochemistry (21-23)The primary 
objectives of CNS Tissue Banking in ALS should be to: 
 
1. Provide access to well documented brain and spinal cord tissues for 
research. 
2. Provide optimal tissue for a wide range of scientific techniques and 
applications. 
3. Increase the awareness of the importance of studying human brain tissue 
amongst patients and their care givers (and crucially to reassure them that it will not 
delay funeral arrangements or affect the external body appearance). 
4. Optimize procedures for the recruitment of CNS tissue donors.  
5. Minimize time from death to tissue procurement and freezing or fixation.  
6. Pathologically confirm the disease status of the tissue.    
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Informed consent 
 
All studies involving human subjects require IRB/REC approval, and there are 
specific considerations in relation to the storage and use of human tissue (thought 
this does not usually include biofluids unless they have an appreciable cellular 
content), and separately for use of any genetic information. It is essential to consider 
obtaining specific consent for samples to be shared at a later date with local as well 
as international collaborators, including those focused on other neurodegenerative 
disorders.  Recognition that such collaborations may be in the commercial sector is 
also important. 
 
Quality control 
 
This concept embraces the entire lifetime of a sample and putative biomarker and 
should include: 
1. pre-analytical tests such as stability in the discovery phase. 
2. tests of accuracy of established analytical methods. 
3. determination of reference values for validated tests, which may include 
participation in quality insurance schemes and strategies to audit cutoff 
values. 
4. assurance that the accuracy of any assay should be better than the variation 
between groups. 
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Biomarker discovery platforms 
 
There are numerous technologies currently in use for ALS biomarker discovery and 
validation efforts. 
 
Proteomics 
 
To date, the most common methodological platform used for untargeted biomarker 
discovery efforts is proteomics. A schematic overview of quantitative proteomic 
approaches is shown in Figure 1. So far, the search for ALS biomarkers was mainly 
based on the surface enhanced laser desorption ionization (SELDI) technology (for 
review see (2).  Whilst having the advantage that large numbers of individual 
samples from biofluids can be processed without prior pre-fractionation, SELDI as a 
pattern recognition tool usually does not directly reveal the identity of the differential 
protein peaks and huge efforts are often needed subsequently to achieve this task 
(24). Alternatively, the two-dimensional fluorescence difference gel electrophoresis 
(2D-DIGE) system, a protein profiling method that can be interfaced to mass 
spectrometric protein identification in a more direct way, has been used for 
differential proteome analysis of CSF in ALS (25).  
2D gel-based approaches have limitations such as under-representation of certain 
protein classes, low sensitivity, and restricted multiplexing capabilities. To address 
these limitations, gel-free mass spectrometry (MS)-based quantification approaches 
of the shotgun-type have been put forward, though often on the cost of information 
linked to protein integrity. These approaches usually rely on stable isotopes, either 
introduced by chemical tagging (e.g. iTRAQ) or metabolic labeling (e.g. SILAC) 
(Figure 2). Here, potential drawbacks include the variation of labeling efficiency in 
iTRAQ and the requirement of cultured cells for SILAC, preventing direct application 
to human material. In this regard, very recent spike-in versions of the SILAC 
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approach (26) are promising at least for tissue samples, though some bias may be 
introduced through the reference proteome. With the advancements in liquid 
chromatography (LC) and MS, label-free quantification is currently emerging as a 
powerful technique with the potential to complement stable isotope-based 
approaches (see for example (27) for an experimental comparison). Based on the 
software-assisted comparison of peptide intensities within separate LC-MS/MS runs, 
this technique features high sensitivity and dynamic range, unlimited multiplexing 
capabilities, and low running costs, making it ideally suitable for biomarker discovery 
from biofluids. However, as the samples to be compared are not mixed at any time 
(like in stable isotope labeling workflows), accuracy of quantification is an issue  and 
the inherently higher variability has to be compensated by technical replicates. An 
early form of label-free quantification has even been used for protein pattern 
classification and identification in CSF from ALS patients (28). 
 
Biomarker discovery typically involves searching for low-abundance proteins and 
proteins of small molecular weight such as cytokines and trophic factors.  Detection 
of these small and low abundant proteins are  that can be detected with multiplex 
antibody based platforms can provide critical data on disease states and can’t be 
overlooked in a biomarker profile (29, 30).  A targeted proteomic approach is 
important to consider, given that the typical dynamic range of quantitative proteomic 
approaches (2-4 orders of magnitude) is far from being sufficient to cover the entire 
protein concentration range of CSF (8 orders of magnitude, (2)) or plasma/serum (10 
orders of magnitude), such biofluids must be depleted of high-abundance proteins to 
shift the quantifiable portion of the proteome towards minor (potentially pathology-
specific) components. Antibody-based depletion of up to 20 major proteins and resin-
based affinity removal of albumin and IgG are common pre-fractionation strategies 
for both serum (31) and CSF (32).  More recently, an alternative strategy based on 
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the use of a combinatorial hexapeptide ligand library has been introduced (33) and 
used for an in-depth exploration of the CSF proteome (34). 
The targeted validation phase of biomarker discovery workflow has been expedited 
due to the more recent transfer of the well-established selected reaction monitoring 
technology (SRM; also known as multiple reaction monitoring, MRM) from the small 
molecule field into proteomics (35).  This is an easy-to-operate mass spectrometric 
method for the accurate quantitation of (pre-defined) proteins from complex mixtures, 
with the potential to overcome antibody-based assays bottlenecks of biomarker 
validation (which typically involve antibody-based assays).  For absolute quantitation, 
SRM assays require stable isotope-labeled standards of the targeted proteotypic 
peptides, a high demand that hampered broad applicability of SRM-MS in routine 
clinical proteomics so far. This is expected to change with the success of 
international initiatives like the human Proteome Detection and Quantitation Project 
(hPDQ) so that in future SRM-MS may bridge the gap between discovery proteomics 
and clinical assay development. 
The proteomic and perhaps any of the biomarker analyses are unlikely to identify a 
single protein that will provide diagnostic and therapeutic insights but rather a 
biomarker panel or “finger print” is more likely.  Therefore, data analysis is as critical 
as the platform chosen to provide the biomarker.  For example, multifactorial analysis 
of analyte expression and crossvalidation in a ‘leave one out’ strategy for determining 
how well a protein panel (fingerprint) is associated with disease classification should 
be considered as the biomarker strategies go forward (29, 30). 
 
RNA and DNA analysis  
 
Biomarker discovery in the central nervous system using the available micro-array 
platforms for tissue RNA-profiling is limited by the cell based heterogeneity and 
complexity.  To circumvent this problem and obtain cell-specific markers of disease 
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initiation and progression, laser-capture microdissection has become a viable route 
to explore the contribution to the pathology of different cellular entities (36).  The 
discovery of the role of particularly vulnerable portions of RNA like the microRNAs, 
non-coding RNAs that post-transcriptionally regulate gene expression and may 
contribute to human diseases including ALS (37), has accentuated the debate on the 
reliability of the commonly used techniques of RNA extraction and storage and their 
effect on RNA integrity.   
 
Similar to other human disorders, ALS may arise from the acquisition of somatic, 
genetic and epigenetic alterations leading to changes in gene sequence, structure, 
copy number and expression. Therefore, the most appropriate investigative tools 
must allow serial analysis of gene expression in parallel with high-throughput DNA 
sequencing to define point mutations, rearrangements and copy-number changes.  
As systems biology evolves into the definition of new types of biological 
macromolecules, a comprehensive analysis of transcriptomes will have to include the 
characterization of microRNAs and of protein-DNA interactions. miRNA and mRNA in 
exosomes are probably more stable and therefore more suitable for biomarker 
studies. 
 
Metabolomics 
Metabolomics is a complementary technique to genomics, transcriptomics and 
proteomics that aims to study the metabolome in a holistic way. The first global 
metabolomic studies in relation to ALS reported reduced levels of metabolites and 
points towards a general depletion of metabolites in blood (38)  and CSF (39).. For 
metabolomic analysis even stricter preanalytic precautions have to been undertaken 
and were set-up by the Metabolomic standards initiative (40) 
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Lipidomics  
 
The role of lipids in cells and tissue physiology is demonstrated by a large number of 
studies confirming the disruption of lipid metabolic enzymes and pathways in the 
development of several human conditions, including neurodegenerative disorders. 
Whilst strong evidence linking a disrupted lipid homeostasis to an early alteration of 
the metabolic state is emerging in ALS, deregulated lipid metabolism has been long 
known to be of particular importance in brain injuries and in the development of other 
neurodegenerative conditions. The introduction of tandem mass spectrometry (MS) 
and of liquid chromatography for the resolution of lipid chemistry has revolutionized 
this area of investigation, creating the ground for the large-scale profiling of a vast 
array of lipid classes and the computational demand for handling the large amount of 
data that these techniques generate (41). 
 
One of the most comprehensive repositories of information surrounding lipid 
classifications, metabolic pathways, involvement in disease processes is contained in 
the Nature Lipidomics Gateway (http://www.lipidmaps.org). In this web-based 
resource, practical considerations are discussed with respect to methods of 
sampling, storage, and lipid extraction of red blood cells. An overview of analysis 
tools for lipid determination, of analytical standards to obtain MS spectra and of the 
experimental parameters used for acquisition of MS/MS spectra is also available.  
A caveat in the reliable use of lipidomics to dissect novel disease biomarkers is the 
largely untested effect that diet may have in the lipid profile of the target biological 
fluids or tissues. Diet can cause short and long-term effects, introducing 
“confounding noises” which could interfere with the disease-related changes of 
specific lipid compounds or mediators (42).  
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Conclusions 
 
Biomarker discovery and biobanking are now at the forefront of the global research 
effort in ALS.  Standardized procedures are an essential part of fostering the large 
collaborative effort necessary for a rare disorder such as ALS.  Comprehensive 
clinical information collated by neurologists with ALS expertise is equally vital. 
Biomarker discovery and validation is costly. As well as intellectual cooperation 
amongst scientists, and the continued encouragement of patients to take part in such 
studies, leadership and vision are needed to put forward the imperative that this is a 
vital investment in tackling the imminent global increase in the prevalence of 
neurodegenerative disorders. 
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Table 1. ALS ideal biomarker characteristics 
1. Sensitive and specific for the heterogeneous syndrome of ALS 
2. Detectable prior to the onset of significant wasting/weakness 
3. Discriminate between clinical phenotypes based on: 
a) Upper and lower motor neuron involvement e.g. PMA and PLS 
 
b) Patterns of regional involvement e.g. flail arm/leg, PBP 
c) Cognitive involvement i.e. ALS versus ALS-FTD 
d) Extremes of survival i.e. ‘aggressive’ versus ‘benign’ course 
4. Able to predict regional involvement and the pattern of spread in advance: 
a) Bulbar dysfunction for early gastrostomy 
b) Respiratory dysfunction for early NIV (possibly diaphragm pacing) 
c) Cognitive impairment 
5. Change in a predictable way with disease progression 
6. Sensitivity to confidently judge therapeutic response within weeks of 
challenge 
7. Easily accessible and affordable technology 
8. Practical to measure in the physically disabled patient 
 
ALS- amyotrophic lateral sclerosis 
FTD – frontotemporal dementia 
NIV – non-invasive ventilation 
PBP – progressive bulbar palsy 
PMA – progressive muscular atrophy 
PLS – primary lateral sclerosis 
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Table 2. Categories of biomarker in ALS. 
Category Purpose Current benchmark Challenges 
DIAGNOSTIC To reduce diagnostic 
delay (current mean 
~1 year from 
symptom onset); 
To more rapidly refer 
patients to 
neuromuscular 
specialist; 
To distinguish ALS 
from mimic disorders; 
Permit earlier 
therapeutic 
intervention 
Clinical acumen; 
ALS neurologists in 
tertiary referral centers 
probably >97% sensitive 
and specific, but 
predominately as a result 
of referral delay 
Who are the ‘at risk’ 
population? 
Where is the ‘clinical 
horizon’ in relation to 
pathogenesis? 
The true mimics are 
not healthy controls, 
but pure LMN and 
pure UMN syndromes 
PROGNOSTIC To identify those with 
poor prognosis who 
may require earlier 
intervention or care 
planning; 
Identify the minority 
for whom cognitive 
involvement likely to 
be significant and 
intrusive 
Prognostic modeling of 
survival with clinical 
parameters 
Prognostic modeling 
based on tertiary 
referral center data; 
Need to establish how 
earlier intervention in 
‘aggressive ALS’ 
might actually be 
beneficial; 
Those with ALS-FTD 
often present with 
early dementia before 
motor features are 
apparent 
MONITORING To provide a marker 
of early therapeutic 
benefit in clinical 
trials; 
Reduce size and 
duration of studies; 
Reduce need for 
placebo arms 
Survival as main 
endpoint, which requires 
trials of >200 patients 
over 12-24 months; 
ALSFRS-R and FVC are 
alternative surrogate 
endpoints 
Heterogeneous 
syndrome of ALS may 
distort all trial 
outcome measures 
due to different 
efficacy across 
phenotypes 
MECHANISTIC Biomarkers may 
provide clues to 
pathogenesis via 
pathway analysis and 
thence provide new 
candidates 
Cellular inclusions e.g. 
TDP-43 and FUS 
indicate abnormal RNA 
processing may be 
important in 
pathogenesis 
Distinguishing 
pathogenic pathways 
from epi-phenomena 
 
ALS- amyotrophic lateral sclerosis 
ALSFRS-R – revised ALS functional rating score 
FTD – frontotemporal dementia 
FVC – forced vital capacity 
LMN – lower motor neuron 
UMN – upper motor neuron 
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Table 3. Types of control sample in ALS biomarker studies 
Category of 
control Advantage Disadvantage 
Healthy 
‘Pure’ sample; 
Greater sensitivity; 
Spouses of patients easily 
available resource 
Ethical approval for invasive procedures 
especially spinal tap, although research 
experience is reassuring and should be pro-
actively emphasised in IRB/REC applications; 
Age-matching additionally challenging; 
Possibly reduced specificity 
‘Ward traffic’ i.e. as 
part of routine 
investigation with 
additional 
sampling volume 
Availability; 
Ethical approval and 
consent easier to obtain as 
it is part of routine care 
Diagnosis may be idiopathic e.g. ‘headache’ or 
‘parasthesiae’, with a need for follow-up to 
categorise later as further information comes to 
light (and ethical approval in this respect); 
Experience from lumbar drainage in Normal 
Pressure Hydrocephalus suggests multiple 
confounds may exist  
Other 
neurodegenerative 
disorders 
Explore specificity of 
putative markers, especially 
neuronal; 
FTD particularly relevant to 
ALS 
Scarcity; 
Relevance to ALS? 
Poor clinical diagnostic accuracy  
Clinical ‘mimics’ 
e.g. multifocal 
motor neuropathy 
with conduction 
block (MFMN), 
Kennedy’s 
syndrome, cervical 
spondylosis 
Value as source for truly 
diagnostic biomarkers 
Scarcity; 
Limited value in current clinical practice; 
Mimics may not be neurodegenerative in 
pathogenesis e.g. MFMN, spondylosis 
Neuro-
inflammatory 
diseases 
Relatively common; 
Explore specificity of 
putative markers, especially 
glial; 
May have ‘mimic’ potential 
e.g. Primary Progressive 
MS versus PLS 
Relevance of primary immune-based conditions 
to ALS, including age, natural history, treatments? 
 
ALS- amyotrophic lateral sclerosis 
FTD – frontotemporal dementia 
MFMN – multifocal motor neuropathy with conduction block 
MS – multiple sclerosis 
PLS – primary lateral sclerosis 
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Table 4. Desirable minimum clinical dataset for ALS biomarker studies. 
Category Clinical information 
Generic (ALS and 
controls) 
Age 
Gender 
Ethnicity 
Drugs 
Past medical history 
Family history of neurodegenerative disorders (back two 
generations) 
Phenotype (ALS) Diagnostic certainty (ALS by revised El Escorial criteria plus PLS 
or PMA), confirmed each time points 
Symptom onset (mo/yr) 
Date of diagnosis 
Site of onset (bulbar, upper/lower limb, respiratory) 
Regional phenotypes (flail arm, flail leg, Progressive Bulbar 
Palsy, Upper versus Lower motor neuron-predominant ALS, 
cognitive involvement e.g. ALS-FTD) 
Evaluation (ALS) ALSFRS-R 
Forced Vital Capacity 
Upper/Lower Motor Neuron involvement 
Body Mass Index 
Cognitive assessment e.g. Verbal Fluency Index 
Interventions (ALS) Gastrostomy 
Non-invasive ventilation 
Cough-assist device 
Tracheostomy 
Date of death (with consideration of stratification of patients 
according to time of sampling in relation to overall disease 
course) 
 
ALS- amyotrophic lateral sclerosis 
ALSFRS-R – revised ALS functional rating score 
FTD – frontotemporal dementia 
PMA – progressive muscular atrophy 
PLS – primary lateral sclerosis 
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Table 5. Strengths and weaknesses among biomarker sources 
 
Characteristic Blood1 CSF Urine Saliva Skin Muscle 
Proximity to CNS 
pathology ++ +++ + + + + 
Less molecular 
complexity + + ++ +++ ++ ++ 
Less invasive 
 
++ + +++ +++ + + 
Practicality of 
sampling +++ ++ +++ ++ + + 
Ease of handling 
for storage ++ +
2 ++ + + + 
Resistance to 
exogenous drug 
contamination 
+ +++ + ++ ++ ++ 
Candidate 
molecules to date ++ +++ + + + + 
Potential for 
DNA/RNA 
analysis 
+++ + + ++ +++ +++ 
 
+++ = Highly significant 
++ = Significant 
+ = Low significance 
 
1
 plasma versus serum needs to be specified - serum may have advantages for the 
stability of some proteins e.g. immunoglobulins. EDTA sample will be needed for 
DNA or RNA studies 
 
2
 bloody tap contamination potential and the particular need for rapid centrifugation 
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Figure 1. Roadmap for biomarker discovery, biobanking and implementation of 
neurochemical markers in ALS. 
 
Figure 2. ‘Quantification tree’ showing the most common approaches for proteome 
profiling in discovery proteomics. 
 
SELDI and 2D-DIGE reveal only pattern information in the first instance, but 2D-
DIGE (in contrast to SELDI) can be readily interfaced to mass spectrometric protein 
identification. MS-based approaches, which reveal both protein profile and identity, 
branch into stable isotope labeling-based and label-free techniques. Stable isotopes 
can be introduced by chemical tagging (e.g. iTRAQ) or by metabolic labeling (e.g. 
SILAC). SILAC can only be applied as a spike-in version to human material as it 
requires metabolic labeling of proteins in cell culture. For label-free quantification, 
peptide intensities are compared within separate LC-MS/MS runs. Abbreviations: 
SELDI, Surface-enhanced laser desorption isonization; 2D-DIGE, two-dimensional 
fluorescence difference gel electrophor sis; MS, mass spectrometry; SILAC, stable 
isotope labeling with amino acids in cell culture; iTRAQ, isobaric tag for relative and 
absolute quantitation; LC, liquid chromatography. 
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